Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-11
2008-11-04
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S543000, C548S525000, C549S383000
Reexamination Certificate
active
07446124
ABSTRACT:
Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
REFERENCES:
patent: 3668222 (1972-06-01), Hauser
patent: 4636195 (1987-01-01), Wolinsky
patent: 5480906 (1996-01-01), Creemer et al.
patent: 5602278 (1997-02-01), Kirkpatrick
patent: 6703414 (2004-03-01), Powis et al.
patent: 7081475 (2006-07-01), Powis et al.
patent: 2003/0109572 (2003-06-01), Powis
patent: 2006/0063824 (2006-03-01), Kirkpatrick et al.
patent: 2006/0128793 (2006-06-01), Zask et al.
patent: 2006/0167080 (2006-07-01), Powis et al.
patent: 1435941 (2006-08-01), None
patent: 1686124 (2006-08-01), None
patent: 2 302 021 (1997-01-01), None
patent: 2302021 (1997-08-01), None
patent: WO 90/01969 (1990-03-01), None
patent: WO 90/03768 (1990-04-01), None
patent: WO 03/024183 (2003-03-01), None
patent: WO 2007/008200 (2007-01-01), None
Wipf et al., Org. Biomol. Chem. (2004), vol. 2, pp. 1911-1920.
Norman et al., J. Med. Chem. (1996), vol. 39, pp. 1106-1111.
submitted in copending U.S. Appl. No. 11/618,036.
Brevis et al., Faranoxi—A New Antitumor Agent, 1996, J. Chemo. 8(1):67-69.
Zalgevicience et al., Embryotoxicity and Teratogenicity of Some Derivatives of Chloroethylaminophenylacetic Acid 1998, Pathology Oncol. Res. 4(1):27-29.
Haefliger et al., Selektive Funktionalisierung von Wortmannin mit Hilfe einer Furanring-Maskierung. 1975, Helvetia Chimica Acta 58(6): Nr, 179-180, pp. 1620-1628.
Norman et al., Studies on the Mechanism of Phosphiadylinositol 3-Kinase Inhibition of Wortmannin and Related Analogs, 1996, J. Med. Chem. 29:1106-1111.
Langer, New Methods of Drug Delivery, 1990, Science 249;1527-1533.
Mathiowitz et al., Photochemical Rupture of Microcapsules: A Model System, 1981, J. App. Poly. Sci. 26:809-822.
Kohn, Current Trends in the Development of Synthetic Materials for Medical Applicatons, 1990, Pharmaceutical Technology, 14(10):32-41.
Folch et al., A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues, 1957, J. Biol. Chem. 226: 497-509.
Clarke et al., Alkaline ο→N-transacylation, 1981, BioChem. J. 195:301-306.
Auger et al., Separation of Novel Polyphosphoinositides, 1990, Methods in Inositide Research, pp. 159-166, Irvine ed., Raven Press Ltd., New York, NY.
Lala et al., Role of nitric and oxide in tumor progression; Lessons from experimental tumors, 1998, Cancer and Metastasis Reviews 17(1);91-106.
Golub et al., Molecular Classification 1999, Science 286:531-537.
Kirkpatrick Lynn
Powis Garth
Wipf Peter
Arizona Board of Regents, Acting on Behalf of the University of
Pepper Hamilton LLP
Prolx Pharmaceuticals Corp.
Solola Taofiq A
The University of Pittsburgh
LandOfFree
Wortmannin analogs and methods of using same in combination... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Wortmannin analogs and methods of using same in combination..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wortmannin analogs and methods of using same in combination... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036619